Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects

HIV Clinical Trials

Volumn 10, Issue 6, 2009, Pages 356-367

  Carosi, G ^a   Lazzarin, A ^b   Stellbrink, H ^c   Moyle, G ^d   Rugina, S ^e   Staszewski, S ^f   Givens, N ^g   Ross, L ^g   Granier, C ^g   Ait Khaled, M ^g   Leather, D ^g   Nichols, W G ^g  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c IPM Study Center   (Germany)

^d CandW   (United Kingdom)

^e Spitalul Clinic Municipal Constanta   (Romania)

^f GOETHE UNIVERSITY   (Germany)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Abacavir; Fosamprenavir; HIV; Ritonavir

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS ZIDOVUDINE; LOPERAMIDE; RITONAVIR; VIRUS RNA;

ACUTE HEPATITIS; ADULT; AGED; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; CARBAMATES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERLIPIDEMIAS; LAMIVUDINE; LIPOPROTEINS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 76749143029     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1006-356     Document Type: Article

References (21)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed May 5, 2009.
3. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. 2008. Available at: http:// www. europeanaidsclinicalsociety.org/guidelinespdf/ 1- Treatment-of-HIV-Infected-Adults.pdf.
4. Cuzin L, Allavena C, Morlat P, Dellamonica P. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: Is there a best choice for antiretroviral-naive HIV-1 infected patients? AIDS Rev. 2008;10:205-211.
5. Boyd M. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS. 2009;4(3):194-199.
6. Cui Y, Blumenthal RS, Flaws JA. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413-1419.
7. D:A:D Study Group. Class of antiretoviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
8. Dubé MP, Stein JH, Aberg JA, et al, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in Human immunodeficiency Virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
9. Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2007;51:560-565.
10. Hicks C, DeJesus E, Sloan L, et al. Once daily fosamprenavir (FPV) with a reduced dose of ritonavir (RTV), given with abacavir (ABC)/lamivudine (3TC) combination tablet: a planned Week 24 interim analysis of the REDUCE Study. In: Program and abstracts of the Ninth International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, UK. Abstract P2.
11. French ANRS AC11 Group. 2006. HIV-1 genotypic drug resistance interpretation's algorithms. Table of rules 2006. Available at: http://www.hivfrenchresistance.org/ 2006/tab2.
12. Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004. Available at: http://www3.niaid.nih. gov/research/resources/ DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med. 2008;16(5):138-145.
14. Lan KKG, Wittes J. The B-value: a tool for monitoring data. Biometrics. 1988;44:579-585.
15. Hughes S, Cuffe R, Lieftucht A, Nichols WG. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial. Pharmaceut Statist. 2008. Published online in Wiley InterScience (www.interscience. wiley.com). DOI: 10.1002/pst.323.
16. NCEP (National Cholesterol Education Program). Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Available at: http:// www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed December 22, 2008.
17. Ortiz R, DeJesus E, Khanlou H, et al. efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2009;22(12):1389-1397.
18. Molina J, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):645-655.
19. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridaemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B.
20. Badiou S, Thiebaut R, Aurillac-Lavignolle V, et al. Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients. J Infect. 2008;57:47-54.
21. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:-1528-1533.